Wave Life Sciences Ltd. (WVE) Stock Price & Analysis
Wave Life Sciences Ltd. (WVE) rose 0.52% to USD 5.81 as of July 25, 2026 at 07:28 UTC, according to Nexqual real-time market data.
WVE last closed at USD 5.78; the session ranged USD 5.74–5.89 on volume of 2,003,663 shares. Market capitalization is $1.12B, with a 52-week range of USD 5.02–21.73 (NGM). Source: Nexqual, July 25, 2026 at 07:28 UTC.
Key Statistics (as of July 25, 2026 at 07:28 UTC)
| Price | USD 5.81 |
|---|---|
| Change | ▲ 0.52% (up) |
| Previous Close | USD 5.78 |
| Open | USD 5.8 |
| Day Range | USD 5.74 – 5.89 |
| 52-Week Range | USD 5.02 – 21.73 |
| Volume | 2,003,663 shares |
| Market Cap | $1.12B |
| Exchange | NGM |
Technical Analysis (WVE)
Nexqual's technical model rates WVE "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 07:28 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 47.85 (neutral) |
| vs SMA50 | Below (USD 6.07) |
| MACD | -0.1 (negative) |
Analyst Ratings (WVE)
Wall Street analysts rate WVE "None" based on 16 analysts, with a mean price target of USD 21.94 (range USD 12–43), per Nexqual as of July 25, 2026 at 07:28 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 16 |
| Mean Target | USD 21.94 |
| High Target | USD 43 |
| Low Target | USD 12 |
| Buy / Hold / Sell | 16 / 0 / 0 |
Earnings (WVE)
| Next Earnings Date | 2026-07-30 |
|---|---|
| EPS Estimate | USD -0.3 |
| Revenue Estimate | $7.10M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD -0.13 vs est -0.31 ▲ beat |
| 2025-12-31 | USD -0.3 vs est -0.26 ▼ miss |
| 2025-09-30 | USD -0.32 vs est -0.3 ▼ miss |
| 2025-06-30 | USD -0.31 vs est -0.28 ▼ miss |
Source: Nexqual, July 25, 2026 at 07:28 UTC.
Financials & Fundamentals (WVE)
| Total Revenue | $71.80M |
|---|---|
| Revenue Growth (YoY) | +316.90% |
| Gross Margin | -164.07% |
| Operating Margin | -81.83% |
| Profit Margin | -255.70% |
| ROE | -53.10% |
| Debt / Equity | 3.07 |
| Current Ratio | 11.26 |
| Total Cash | $544.59M |
| Total Debt | $15.71M |
| Free Cash Flow | $-125.72M |
Source: Nexqual, July 25, 2026 at 07:28 UTC.
Financial Health Score (WVE)
Nexqual rates Wave Life Sciences Ltd.'s overall financial health "Weak" across five dimensions, as of July 25, 2026 at 07:28 UTC.
| Growth | Critical — Revenue -61% YoY (annual), sharp decline |
|---|---|
| Profitability | Weak — Small revenue base — building scale |
| Balance Sheet | Strong — $545M cash vs $16M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$126M, burning cash |
| Efficiency | Critical — ROE -53%, ROA -28.2% |
Ownership (WVE)
| Insider Ownership | +15.88% |
|---|---|
| Institutional Ownership | +82.67% |
| Shares Outstanding | 192.40M |
| Float | 90.11M |
| Short % of Float | +10.86% |
Source: Nexqual, July 25, 2026 at 07:28 UTC.
Leadership (WVE)
Wave Life Sciences Ltd. is led by Paul B. Bolno (age 51), President, CEO & Director, per Nexqual as of July 25, 2026 at 07:28 UTC.
| President, CEO & Director | Paul B. Bolno (age 51) |
|---|---|
| Founder & Director | Gregory L. Verdine (age 66) |
| CFO & Principal Accounting Officer | Kyle B. Moran (age 54) |
| Chief Technology Officer | Chandra Vargeese (age 64) |
| Chief Scientific Officer | Erik Ingelsson |
Major Backers & Investors (WVE)
Notable institutional backers of Wave Life Sciences Ltd. include RA Capital Management, L.P., GSK plc, Maverick Capital Ltd., according to Nexqual as of July 25, 2026 at 07:28 UTC.
Active Investors
| Investor | Stake |
|---|---|
| RA Capital Management, L.P. | 14.02% |
| GSK plc | 9.48% |
| Maverick Capital Ltd. | 5.28% |
| Price (T.Rowe) Associates Inc | 4.52% |
| T. Rowe Price | 3.02% |
| Driehaus Capital Management, LLC | 2.82% |
| Federated Hermes, Inc. | 2.76% |
| FMR, LLC | 2.7% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.68% |
Source: Nexqual, July 25, 2026 at 07:28 UTC.
From Wave Life Sciences Ltd.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Our HD Program WVE-003 is our stereopure allele-selective oligonucleotide that incorporates our proprietary PN chemistry and is designed to selectively target rs362273, a variant of the single nucleotide polymorphism ("SNP"), "mHTT SNP3", associated with the disease-causing mHTT mRNA transcript within the HTT gene (Iwamoto et al., MTNA).
- PRISM: Our proprietary discovery and drug development platform Our PRISM platform demonstrates the powerful convergence of best-in-class chemistry with human genetics.
- Our Proprietary Chemistry Backbone Stereochemistry In our foundational Nature Biotechnology paper (Iwamoto N, et al.
- Nature Biotechnol. 2017;35(9):845-851), we described our studies using our proprietary chemistry to design and synthesize stereopure oligonucleotides and oligonucleotide mixtures based on mipomersen.
Partnerships
- With respect to the $50.0 million equity investment referred to above, simultaneously with our entry into the GSK Collaboration Agreement, we entered into a share purchase agreement with Glaxo Group Limited ("GGL"), an affiliate of GSK, pursuant to which we agreed to sell to GGL 10,683,761 of our ordinary shares at a purchase price of $4.68 per share, for an aggregate purchase price of approximately $50.0 million (the "GSK Equity Investment").
- Treatments are available to help deal with intestinal bleeding, fluid in the abdomen, nutritional issues, and other complications from scarring of the liver, but ultimately many patients will progress towards requiring a liver transplant.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SRRK | Scholar Rock Holding Corporatio | USD 47.67 | ▼ 1.3% |
| VYGR | Voyager Therapeutics, Inc. | USD 3.1 | ▲ 0% |
| CTMX | CytomX Therapeutics, Inc. | USD 3.24 | ▼ 2.7% |
| SLDB | Solid Biosciences Inc. | USD 7.83 | ▼ 3.33% |
| PTGX | Protagonist Therapeutics, Inc. | USD 136.11 | ▲ 0.49% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 07:28 UTC. This page is informational and not investment advice.